PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
PharmaTher Holdings Ltd. has announced an update on their Priority ANDA for Ketamine, indicating that their response to the FDA’s preliminary deficiency findings will be submitted shortly, with the aim of meeting the GDUFA goal date of April 29, 2024. The company is poised to address any additional FDA feedback and is committed to resolving the U.S. ketamine shortage by ensuring their product complies with FDA manufacturing and prescription standards. PharmaTher also plans to seek international approvals post U.S. launch and explore ketamine’s therapeutic potential for various health conditions.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.
